Johnson & Johnson
NYSE: JNJ
FDA Prioritizes New Hepatitis C Drug
Is Johnson & Johnson's simeprevir destined to be the first next-gen hepatitis-C drug.Biosense Webster Reports Compelling Results from Ground-Breaking SMART-AF IDE Study on the Safety an
A Fool recaps first-quarter earnings bright spots around the pharmaceutical industry.
Vivus Increases Board to 9 Members
The pharma company announces its second and third new board members in two weeks.5 Things I Learned Reading Johnson & Johnson's Annual Report
Details of one of the world's greatest companies.